Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis aid pathologists in providing faster, more accurate patient diagnoses in breast cancer
In combination with the VENTANA DP 200 slide scanner and Roche uPath enterprise software, the new algorithms provide innovative digital pathology solutions to advance personalised healthcare
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year. About 15 to 20 percent of women diagnosed with breast cancer are HER2 positive
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer.